HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Paulus on the Rationale for Utilizing an External Control Arm in a Single-Arm HER2+ Breast Cancer Trial

June 23rd 2025

Jessica Paulus, ScD, explains the rationale for utilizing an external control arm in a single-arm phase 2 HER2-positive metastatic breast cancer trial.

Dr Tarantino on the Evolving Role of THP in HER2+ Metastatic Breast Cancer

June 19th 2025

Paolo Tarantino, MD, discusses the evolving role of trastuzumab plus pertuzumab and chemotherapy in HER2-positive breast cancer after DESTINY-Breast09.

T-DXd Maintains Efficacy in HR+/HER2-Low or HER2-Ultralow Breast Cancer Irrespective of Mutational Subtype

June 1st 2025

T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.

Dr Desai on the PATINA Study of a Palbociclib-Based Regimen in HR+/HER2+ Metastatic Breast Cancer

May 30th 2025

Neelam Desai, MD, highlights the phase 3 PATINA study evaluating a palbociclib-based regimen in HR-positive/HER2-positive metastatic breast cancer.

Dr Bardia on Efficacy Data from the DESTINY-Breast06 Trial of T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer

May 29th 2025

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.

Dr Ali on the Need to Refine Predictive Strategies for Endocrine Sensitivity in HER2-Low Breast Cancer

May 28th 2025

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Dr Tarantino on Directions for Prospective Research in HER2+ Metastatic Breast Cancer

May 27th 2025

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

Dr McCann on the Biologic Heterogeneity Within HER2+ Breast Cancer

May 26th 2025

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25th 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

Patient-Centered Decisions and Evolving Treatment Landscape for HER2+ Metastatic Breast Cancer

May 23rd 2025

Panelists discuss how treatment decisions in later-line settings should incorporate clinical trials, patient preferences regarding quality of life, medication scheduling, financial considerations, and previous adverse effect experiences, while also addressing special considerations for brain metastases.

Statin Use Is Not Associated With Improved Outcomes in Early HER2+ Breast Cancer

May 22nd 2025

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

Five Under 5: Top Oncology Videos for the Week of 5/11

May 18th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

The OncFive: Top Oncology Articles for the Week of 5/11

May 17th 2025

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

May 16th 2025

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer

May 16th 2025

Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

May 16th 2025

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

May 16th 2025

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Navigating the Data: Later-Line Systemic Therapies for HER2+ Metastatic Breast Cancer

May 16th 2025

Panelists discuss how fourth-line treatment options include margetuximab (which interacts better with the immune system), neratinib-capecitabine (an irreversible pan-HER inhibitor), and antibody-drug conjugates (ADCs) with different payloads, though toxicity profiles must be considered.

Expert Insights on Third-Line Treatment Decisions for HER2+ Metastatic Breast Cancer

May 16th 2025

Panelists discuss how third-line treatment options after T-DXd progression include T-DM1 and the HER2CLIMB regimen (tucatinib-capecitabine-trastuzumab), with consideration of brain metastases as a key factor in treatment selection.

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

May 15th 2025

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.